Answers are grounded in this paper and cite their sources.
Literature review highlights wide variability in SBRT dose reporting for early-stage lung cancer, indicating the need for uniform prescription metrics to accurately evaluate outcomes.
INTRODUCTION: Stereotactic body radiation therapy is increasingly used in the treatment of early-stage lung cancers. Guidelines provide indications regarding the constraints to the organs at risk (OARs) and the minimum coverage of the planning target volume but do not suggest optimal dose distribution. Data on dose distribution from the different published series are not comparable due to different prescription modalities and reported dose parameters. METHODS: We conducted a review of the published data on dose prescription, focusing on the role of homogeneity on local tumor control, and present suggestions on how to specify and report the prescriptions to permit comparisons between studies or between cases from different centers. CONCLUSIONS: To identify the dose-prescription modality that better correlates with oncologic outcomes, future studies should guarantee a close uniformity of dose distribution between cases and complete dose parameters reporting for treatment volumes and OARs.
No takes yet. Share an insight, caveat, or question.
Merlotti et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: